| Literature DB >> 36189360 |
Maria Karoliny da Silva Torres1,2, Felipe Teixeira Lopes1,2, Aline Cecy Rocha de Lima1,2, Carlos Neandro Cordeiro Lima1,2, Wandrey Roberto Dos Santos Brito1,2, Janete Silvana S Gonçalves1,2, Onayane Dos Santos Oliveira1,2, Vanessa de Oliveira Freitas1, Bernardo Cintra Dos Santos1, Renata Santos de Sousa1,2, Jayanne Lilian Carvalho Gomes1, Bruno José Sarmento Botelho1, Ana Carolina Alves Correa1, Luiz Fernando A Machado1,2, Rosimar Neris Martins Feitosa1,2, Sandra Souza Lima1,2, Izaura Maria Vieira Cayres Vallinoto1,2, Antonio Carlos R Vallinoto1,2.
Abstract
In Brazil, the coronavirus disease 2019 (COVID-19) epidemic spread rapidly in a heterogeneous way, mainly due to the different socioeconomic and behavioral characteristics of different regional populations and different evaluation periods. We performed a cross-sectional study including 1,337 individuals (first wave = 736/second wave = 601) after the first two waves of COVID-19 in the city of Belém, the capital of the state of Pará. The detection of IgG anti-SARS-CoV-2 antibodies was performed using an enzyme-linked immunosorbent assay test followed by statistical analysis using the RStudio program. Our results showed an increase in the seroprevalence (first wave= 39.1%/second wave= 50.1%) of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG antibodies in the population of Belém from the first to the second pandemic wave. Advanced age, primary or secondary education level, lack of social isolation, and a low frequency of protective mask use were considered risk factors for SARS-CoV-2 infection during the first wave compared to the second wave. This study is one of the firsts to provide important information about the dynamics of virus circulation and the groups vulnerable to exposure in the two major periods. Our data emphasize the socioeconomic characteristics of the affected population and that nonpharmacological prevention measures are crucial for combating the pandemic.Entities:
Keywords: Amazon; Belém; Brazil; COVID-19; SARS-CoV-2; seroepidemiology
Mesh:
Substances:
Year: 2022 PMID: 36189360 PMCID: PMC9524613 DOI: 10.3389/fcimb.2022.932563
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 6.073
Socioeconomic characteristics, prevalence of comorbidities, and risk of SARS-CoV-2 infection.
| Variables | First Wave (%) | 95% IC | Second wave (%) | 95% IC | Univariate analysisOR (95% IC) |
| Multivariate analysisOR (95% IC) |
|
|---|---|---|---|---|---|---|---|---|
| Total | 275 (39.1) | – | 284 (50.1) | – | – | |||
| Sex | ||||||||
| Female | 179 (65.1) | 59–70 | 183 (64.4) | 58–70 | (Ref) | |||
| Male | 96 (34.9) | 29–40 | 101 (35.6) | 30–41 | 0.96 (0.67–1.35) | 0.8009 | ||
| Age | ||||||||
| ≤18 | 18 (26.9) | 3–9 | 20 (50.0) | 4–10 | (Ref) | (Ref) | ||
| 19–29 | 55 (47.4) | 15–24 | 86 (96.6) | 24–35 | 0.72 (0.35–1.48) | 0.3784 | ||
| 30–39 | 29 (31.9) | 6–14 | 58 (33.7) | 15–25 | 0.55 (0.2–1.20) | 0.1383 | ||
| 40–49 | 48 (38.4) | 13–21 | 44 (42.7) | 11–19 | 1.21 (0.5–2.58) | 0.6183 | ||
| 50–59 | 55 (44.7) | 15–24 | 45 (60.8) | 16–20 | 1.38 (0.65–2.92) | 0.3958 | ||
| 60–69 | 37 (37.0) | 9–17 | 10 (21.7) | 1–5 | 4.11 (1.50–10.5) |
| 6.41 (2.12–19.3) |
|
| ≥70 | 30 (47.6) | 7–14 | 9 (75.0) | 1–5 | 3.58 (1.34–9.56) |
| 3.68 (1.26–10.6) |
|
| NI | 3 (15.8) | – | 12 (54.5) | – | ||||
| Education | ||||||||
| Illiterate | – | – | 02 (0.70) | – | – | * | ||
| Elementary school | 38 (13.8) | 9–17 | 23 (8.10) | 4–11 | 4.80 (2.53–9.11) |
| 3.55 (1.56–8.03) |
|
| High school | 110 (40.0) | 34–45 | 68 (23.9) | 19–28 | 4.58 (2.82–7.44) |
| 3.44 (1.98–5.93) |
|
| Undergraduate school | 89 (32.4) | 36–37 | 102 (35.9) | 30–41 | 3.04 (1.87–4.91) |
| ||
| Graduate school | 38 (13.8) | 9–17 | 84 (29.6) | 24–34 | (Ref) | (Ref) | ||
| NI | 0 | – | 05 (1.76) | – | – | |||
| Skin color | ||||||||
| Yellow | 3 (1.1) | – | 07 (2.46) | 0–4 | 0.40 (0.10–1.65) | 0.2089 | ||
| White | 62 (22.5) | 17–27 | 60 (21.1) | 16–25 | (Ref) | |||
| Black | 36 (13.1) | 9–17 | 58 (20.4) | 15–25 | 0.59 (0.34–1.02) |
| ||
| Brown | 173 (62.1) | 57–68 | 153 (53.9) | 48–59 | 0.70 (1.62–0.74) | 0.7473 | ||
| NI | 1 (0.4) | – | 06 (2.11) | – | ||||
| Income | ||||||||
| ≤ 1 or 2 | 135 (49.1) | 43–55 | 120 (42.3) | 36–48 | 1.22 (0.82–1.80) | 0.3216 | ||
| 3 or 4 | 53 (19.3) | 14–23 | 66 (23.2) | 18–28 | 0.86 (0.53–1.39) | 0.5490 | ||
| ≥5 | 79 (28.7) | 23–34 | 84 (29.6) | 24–34 | (Ref) | |||
| NI | 8 (2.9) | – | 14 (4.93) | – | ||||
| Comorbidity | ||||||||
| Diabetes | 22 (8.0) | 4–11 | 20 (7.04) | 4–10 | 1.15 (0.61–2.15) | 0.6678 | ||
| Asthma | 25 (9.1) | 5–12 | 23 (8.10) | 4–11 | 1.13 (0.62–2.05) | 0.6756 | ||
| Autoimmune disease | 5 (1.8) | – | 05 (1.76) | – | 1.03 (0.29–3.60) | 0.9590 | ||
| Cardiovascular disease | 11 (4.0) | 1–6 | 07 (2.46) | 0–4 | 1.81 (0.70–4.65) | 0.2215 | ||
| Hypertension | 68 (24.7) | 19–29 | 32 (11.3) | 7–14 | 2.64 (1.66–4.16) |
| ||
| Obesity | 13 (4.7) | 2–7 | 10 (3.52) | 1–5 | 1.47 (0.64–3.87) | 0.3626 | ||
| Tuberculosis | 1 (0.4) | – | 0 (0.0) | – | – | |||
| None | 157 (57.1) | – | 176 (62.0) | – | (Ref) | |||
OR, odds ratio; NI, not informed; *, not significant.
Bold means the values are statiscally significant.
Figure 1The frequency of anti-SARS-CoV-2 IgG antibodies according to socioeconomic characteristics. (A) Age-associated seroprevalence. (B) Seroprevalence associated with education level. (C) Seroprevalence associated with skin color. (D) Seroprevalence associated with family income. NI, not informed.
Seropositivity associated with behavioral characteristics after the first and second waves of COVID-19.
| Variables | First wave (%) | 95% IC | Second wave (%) | 95% IC | Univariate analysisOR (95% IC) |
| Multivariate analysisOR (95% IC) |
|
|---|---|---|---|---|---|---|---|---|
|
| 275 (39.1) | 284 (50.1) | ||||||
|
| ||||||||
| Yes | 82 (29.8) | 24–35 | 212 (74.6) | 69–79 | 0.65 (0.44–0.95) |
| ||
| No | 189 (68.7) | 36–74 | 61 (21.5) | 16–26 | (Ref) | |||
| NI | 4 (1.5) | 11 (3.87) | ||||||
|
| ||||||||
| Yes | 234 (85.1) | 80–89 | 251 (88.4) | 84–92 | (Ref) | (Ref) | ||
| No | 39 (14.2) | 10–18 | 21 (7.39) | 4–10 | 1.99 (1.13–3.48) |
| 2.12 (1.13–3.94) |
|
| NI | 2 9 (0.7) | 12 (4.23) | ||||||
|
| ||||||||
| Rarely | 24 (8.7) | 5–12 | 16 (5.63) | 3–8 | 1.15 (0.78–2.91) | 0.2169 | ||
| Many times a day | 250 (90.9) | 87–94 | 252 (88.7) | 85–92 | (Ref) | |||
| NI | 1 (0.4) | 17 (5.63) | ||||||
|
| ||||||||
| Sometimes | 18 (6.5) | 3–9 | 8 (3.7) | 0–4 | 2.89 (1.12–7.40) |
| 3.38 (1.24–9.18) |
|
| Always | 245 (89.1) | 85–92 | 236 (83.1) | 78–87 | (Ref) | (Ref) | ||
| NI | 12 (4.4) | 40 (14.1) | ||||||
|
| ||||||||
| Yes | 106 (38.5) | 32–43 | 129 (45.4) | 39–41 | 0.69 (0.49–0.97) |
| ||
| No | 167 (60.7) | 55–66 | 147 (51.8) | 45–57 | (Ref) | |||
| NI | 2 (0.8) | 8 (2.8) | ||||||
OR, odds ratio; NI, not informed.
Bold means the values are statiscally significant.
Figure 2Behavioral characteristics associated with seropositivity after the first and second waves of COVID-19. *, significant values (p < 0.05); ns, nonsignificant values (p > 0.05).
Figure 3Socioeconomic and behavioral variables associated with the risk of SARS-CoV-2 infection after the first two waves of COVID-19 in the city of Belém.
Figure 4Prevalence and frequency of antibodies and symptoms among symptomatic and asymptomatic individuals. (A) Percentage of +/- anti-SARS-CoV-2 IgG antibodies between symptomatic and asymptomatic individuals. (B) Frequency of symptoms characteristic of COVID-19. ns, not significant.
Prevalence of symptom characteristics of COVID-19 in IgG+ individuals.
| Symptoms | First wave (%) | 95% IC | Second wave 2 (%) | 95% IC |
|
|---|---|---|---|---|---|
| Total | 275 (31.9) | – | 284 (50.1) | – | – |
| Fever | 134 (48.7) | 42–54 | 87 (30.6) | 25–36 |
|
| Headache | 164 (60.0) | 53–65 | 176 (61.9) | 56–67 | 0.8334 |
| Coryza | 130 (47.6) | 41–53 | 143 (50.3) | 44–56 | 0.7240 |
| Cough | 145 (53.5) | 46–58 | 114 (40.1) | 34–45 | 0.0833 |
| Sore throat | 125 (46.2) | 39–51 | 148 (52.1) | 46–57 | 0.9842 |
| Body aches | 161 (58.9) | 52–64 | 132 (46.4) | 40–52 | 0.1276 |
| Abdominal pain | 73 (26.5) | 21–31 | 48 (16.9) | 12–21 |
|
| Diarrhea | 86 (31.3) | 26–36 | 85 (29.9) | 24–36 | 0.8699 |
| Nausea | 59 (21.5) | 16–26 | 57 (20.0) | 15–24 | 0.8222 |
| Vomiting | 23 (8.0) | 0–4 | 24 (8.4) | 5–11 | 0.9062 |
| Loss of smell | 137 (50.5) | 43–55 | 85 (29.9) | 24–35 |
|
| Loss of taste | 132 (48.4) | 42–53 | 89 (31.3) | 25–36 |
|
| Shortness of breath | 65 (24.0) | 18–28 | 48 (16.9) | 12–21 | 0.1306 |
| Fatigue | 130 (48.0) | 41–53 | 118 (41.5) | 35–47 | 0.4419 |
Bold means the values are statiscally significant.